CTLA-4-targeting antisense oligonucleotide (OliPass)

N/A

Report date: 2025/01/26 18:21:09
NME

Base Information

Drug NameCTLA-4-targeting antisense oligonucleotide (OliPass)
Drug Alias NameCTLA-4 Checkpoint Inhibitor (OliPass)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOlipass Co
China Registration ClassN/A

Develop Information

Active CompaniesOlipass Co
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A